Claims
- 1. A method for differentiating one or more pluripotent embryonic stem (ES) cells toward one or more neural cells comprising:
(a) culturing the ES cells at low density in the serum-free media; and (b) allowing said ES cells to differentiate toward the neural cells.
- 2. The method according to claim 1 for differentiating embryonic stem cells to cells with markers characteristic of neural cells comprising:
(a) culturing the embryonic stem cells in a serum free media at low cell density wherein said density is selected to minimize ES cell aggregation of EB formation; (b) allowing said cells to differentiate.
- 3. The method of claim 2 wherein the density is selected as to avoid EB formation.
- 4. The method of claim 1 wherein said cell density is greater than 0 cells/μl to 50 cells/μl.
- 5. The method of claim 4 wherein the cell density is greater than 0 cells/μl to 20 cells/μl.
- 6. The method of claim 5 wherein the cell density is greater than 0 cells/μl to 10 cells/μl.
- 7. The method of claim 6 wherein the cell density is 10 cells/μl.
- 8. The method of claim 6 wherein there is no EB formation.
- 9. The method of claim 7 wherein the differentiating ES cells form at least one neuro sphere.
- 10. The method of claim 1 wherein the differentiating ES cells form at least one neurosphere.
- 11. The method of claim 1 wherein the serum free media further comprises a cytokine.
- 12. The method of claim 11 wherein the cytokine is leukemia inhibitory factor (LIF).
- 13. The method of claim 12 wherein the ES cells differentiate into a primitive neural stem cell, that is pluripotent.
- 14. The method of claim 1 and 12 wherein the serum free media further comprises a growth factor.
- 15. The method of claim 14 wherein the growth factor is selected from the members of the fibroblast growth factor (FCF) family of growth factors.
- 16. The method of claim 15 wherein the growth factor is FGF2.
- 17. The method according to claim 1 wherein the media comprises an inhibitor of TGF-β-related signaling.
- 18. The method of claim 17, wherein the inhibitor is the protein Noggin.
- 19. The method of claim 18 wherein the inhibitor is selected from the Cerebus family of proteins.
- 20. A method for producing secondary neural stem cell colonies comprising:
(a) culturing ES cells in low cell density completely defined serum-free media for a time and under conditions sufficient to differentiate the said ES cells; (b) dissociating and subcloning primary neural cell colonies generated from the said ES cells; and (c) administering a growth factor to the dissociated neural cells.
- 21. A method according to claim 20 wherein the growth factor is selected from among the members of the fibroblast growth factor (FGF) family of growth factors.
- 22. A method according to claim 21 wherein the growth factor is FGF2.
- 23. A method according to claim 20 wherein a cytokine is administered to the dissociated neural cells.
- 24. A method according to claim 23 wherein the cytokine is LIF of B27.
- 25. One or more cell(s) expressing one or more neural precursor cell marker(s) and/or one or more neural-specific mRNA molecule(s), and having multilineage potential.
- 26. A cell according to claim 25 wherein the neural precusor marker nestin is expressed.
- 27. A cell according to claim 25 or 26 wherein the neural-specific mRNA molecule is Fmx2 or HoxB1
- 28. A method according to anyone of claims 1 or 12 for analyzing the role of genes in the regulation of neural fate specification.
- 29. A primitive neural stem cell produced by the method of claim 12 that comprises neural cell markers and is pluripotent.
- 30. A primitive neural stem cell produced comprising at least one neural cell marker and is pluripotent.
- 31. A method of producing a pre-selected cell type derived form a cell of claim 30 comprising, culturing the cells under differentiating conditions that promote formation of the cell type.
- 32. The method of claim 31 wherein the pre-selected cell type is a neural cell, and the differentiating conditions comprise culturing the cell in a serum free media that comprises FGF2.
- 33. A method for screening for modulators of cellular differentiation comprising
(a) culturing pluripotent cells in serum-free media under low density conditions in the presence of the potential modulator; (b) allowing for differentiation of the cells; (c) detecting any differentiation of the cells and cell types generated, if any.
- 34. A method in accordance with claim 33 wherein the modulators comprise any culturing conditions that may modulate cellular differentiation.
- 35. A method for screening for differentiation factors of cellular development comprising:
(a) culturing the cells in serum free media at low cell density in the presence of the differentiation factor; (b) allowing cells to differentiate; (c) detecting differentiation of the cells, if any.
- 36. A method of claim 35 for screening for modulators or differentiation factors of neural cell development.
- 37. A method for screening for differentiation factors of cellular development comprising:
(a) culturing the cells of claim 29 in serum free media, in the present or the differentiation factor. (b) detecting any differentiation of the cells.
- 38. The method of claim 37, wherein the media further comprises FGF2.
- 38. A modulator or differentiation factor detected by the methods of claims 33-37.
- 39. A method according to claim 38 for modulating cellular differentiation.
- 40. The method of claim 1 for obtaining a homogenous uniform cell base.
- 41. The method of claim 40 wherein the cell base is a neural cell base.
- 42. A method for supplying cells for transplantation comprising culturing cells pursuant to the method of claim 1 or 12.
- 43. A method for treating neurodegenerative disorders comprising administering to a patient in need thereof the cells of claim 29.
- 44. A method for the treatment of any disease or conditions resulting from cell loss or function in the neural system comprising administering the cells of claim 29 to a patient in need thereof.
- 45. A method of gene therapy, wherein the cell of claim 29 is modified to express a gene of interest and administering said modified cell to a patient in need thereof.
RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional patent application No. 60/236,394 filed Sep. 29, 2000, entitled “Primitive Neural Stem Cells And Method For Differentiation Of Stem Cells To Neural Cells”.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60236394 |
Sep 2000 |
US |